New breed of drug that reduces deaths from bladder cancer
The medicines, which are known as antibody-drug conjugates (ADCs), carry out chemotherapy-like attacks on cancer cells but don't cause side effects such as hair loss, fatigue and nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2021 Category: Consumer Health News Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news
Recurring Urinary Tract Infections May Play A Role In Bladder Cancer
A recent study published in PLOS Pathogens has found that a DNA-damaging bacterial toxin called colibactin is produced in people with UTIs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 28, 2021 Category: Pharmaceuticals Authors: Anuradha Varanasi, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Study: Bladder cancer is more advanced in South Texas
(University of Texas Health Science Center at San Antonio) A study by the Mays Cancer Center, home to UT Health San Antonio MD Anderson, found bladder cancer is more advanced and more aggressive in South Texas compared to other areas of the U.S. Latinos and women have reduced five-year survival rates from bladder cancer, the analysis also found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 25, 2021 Category: Cancer & Oncology Source Type: news
Bladder Cancer Indication Withdrawn for Durvalumab Bladder Cancer Indication Withdrawn for Durvalumab
AstraZeneca is withdrawing durvalumab ' s indication for the treatment of metastatic bladder cancer after a phase 3 trial showed no survival benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 23, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Oncotarget: MEK is a promising target in the basal subtype of bladder cancer
(Impact Journals LLC) " The @Oncotarget authors demonstrate that MEK inhibitors are a promising targeted therapy for the basal subtype of bladder cancer, and their data indicate that drug screening of 3D cultures provides an important resource for hypothesis generation " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2021 Category: Cancer & Oncology Source Type: news
High-speed radiotherapy can blast away bladder cancer... in just FOUR weeks
A landmark study has proved that an intense 20-day course of the treatment is more effective than lower doses given over six weeks - once the standard option. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2021 Category: Consumer Health News Source Type: news
Know the Signs of Rare But Deadly Gall Bladder, Bile Duct Cancers
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 16, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Hepatology, Oncology, News, Source Type: news
Know the Signs of Rare But Deadly Gall Bladder, Bile Duct Cancers
TUESDAY, Feb. 16, 2021 -- Most people aren ' t aware of the signs of gallbladder or bile duct cancer, but the Rutgers Cancer Institute of New Jersey says they should be.
The gallbladder is a small organ connected to the liver by bile ducts. Its job... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 16, 2021 Category: General Medicine Source Type: news
Know the Signs of Rare But Deadly Gall Bladder, Bile Duct Cancers
Title: Know the Signs of Rare But Deadly Gall Bladder, Bile Duct CancersCategory: Health NewsCreated: 2/16/2021 12:00:00 AMLast Editorial Review: 2/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2021 Category: Cancer & Oncology Source Type: news
New class of drug leads to 30% reduced risk of death for bladder cancer patients
(Queen Mary University of London) A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2021 Category: Cancer & Oncology Source Type: news
Aspirin Linked to Reduced Bladder, Breast Cancer Mortality Aspirin Linked to Reduced Bladder, Breast Cancer Mortality
Regular aspirin use in older people shows no reduction in the incidence of some cancers, but some mortality reductions were seen in an observational study that used data from a large US cohort.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Prostate cancer symptoms: Nocturia could be a sign of the disease - do you have it?
PROSTATE cancer symptoms emerge when the tumour is large enough to press against the urethra - the tube that carries urine from the bladder out of the body through the tip of the penis. What are the signs of the disease? (Source: Daily Express - Health)
Source: Daily Express - Health - January 30, 2021 Category: Consumer Health News Source Type: news